H K Enzymes And Biochemicals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 22-12-2024
- Paid Up Capital ₹ 0.10 M
as on 22-12-2024
- Company Age 19 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 22-12-2024
- Revenue 58.82%
(FY 2022)
- Profit -37.54%
(FY 2022)
- Ebitda -19.25%
(FY 2022)
- Net Worth 13.20%
(FY 2022)
- Total Assets 3.21%
(FY 2022)
About H K Enzymes And Biochemicals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Preeti Doshi and Piyush Doshi serve as directors at the Company.
- CIN/LLPIN
U24230MH2005PTC150963
- Company No.
150963
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Feb 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does H K Enzymes And Biochemicals Private Limited offer?
H K Enzymes And Biochemicals Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API, Fertilizers and Soil Additives, Sulfur Fertilizers, Dyes & Color Additives, Pigment Extenders, Chemical Reagents & Catalysts, Inorganic Salts, Flavours & Aromatics, Artificial Sweetener.
Who are the key members and board of directors at H K Enzymes And Biochemicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Preeti Doshi  | Director | 02-Feb-2005 | Current |
| Piyush Doshi | Director | 02-Feb-2005 | Current |
Financial Performance of H K Enzymes And Biochemicals.
H K Enzymes And Biochemicals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 58.82% increase. The company also saw a substantial fall in profitability, with a 37.54% decrease in profit. The company's net worth Soared by an impressive increase of 13.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of H K Enzymes And Biochemicals?
In 2018, H K Enzymes And Biochemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Nov 2022 | ₹5.00 M | Open |
How Many Employees Work at H K Enzymes And Biochemicals?
Unlock and access historical data on people associated with H K Enzymes And Biochemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of H K Enzymes And Biochemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped H K Enzymes And Biochemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
